Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1 4Phase 1/2 2Phase 3 1Phase 2/3 1

Status

Completed 3Terminated 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 4

Sponsor

Cancer Type

Plasma cell 3Lymphoid 1Genitourinary 1

Conditions

Multiple Myeloma 3Smoldering Multiple Myeloma 1Recurrence 1Prostatic Neoplasms 1Neoplasms, Plasma Cell 1Monoclonal Gammopathy of Undetermined Significance 1Lymphoma, Non-Hodgkin 1Castleman Disease 1

Interventions

pembrolizumab 304Paclitaxel 206Carboplatin 200Gemcitabine 173Cisplatin 139Docetaxel 138Cyclophosphamide 136Nivolumab 129Bevacizumab 118Injections 111fludarabine 96atezolizumab 91Pemetrexed 90Dexamethasone 90Cetuximab 90Fluorouracil 84Irinotecan 77Rituximab 72Capecitabine 72venetoclax 71Azacitidine 70130-nm albumin-bound paclitaxel 67Leucovorin 65Fulvestrant 58Oxaliplatin 57durvalumab 56Trastuzumab 56Lenalidomide 55Ipilimumab 55Midazolam 54

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Phase 1 × INDUSTRY × siltuximab × Clear all
NCT01219010 2015-01-19

A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma

Janssen Research & Development, LLC

Phase 1 Completed
30 enrolled
Plasma cell

Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Neoplasms, Plasma Cell

NCT00412321 2014-07-01

A Safety and Efficacy Study of CNTO 328 in Patients With B-Cell Non-Hodgkin's Lymphoma, Multiple Myeloma, or Castleman's Disease

Centocor, Inc.

Phase 1 Completed
67 enrolled
LymphoidPlasma cell

Castleman Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma

NCT00401765 2014-05-26

A Study of CNTO 328 in Patients With Metastatic Hormone-Refractory Prostate Cancer

Centocor, Inc.

Phase 1 Completed
40 enrolled
Genitourinary

Prostatic Neoplasms

NCT01309412 2014-05-19

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Janssen Pharmaceutical K.K.

Phase 1 Terminated
9 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡